Intracellular A-beta amyloid, a sign for worse things to come?

Molecular Neurobiology

Volumn 26, Issue 2-3, 2002, Pages 299-316

  Echeverria, Valentina ^a   Cuello, A Claudio ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; A ; Phosphorylation; Tau; Transgenic rats

Indexed keywords

AMYLOID BETA PROTEIN; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOSYNTHESIS; BRAIN CELL; BRAIN CORTEX; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; HIPPOCAMPUS; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SENILE PLAQUE;

EID: 0036772311     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:26:2-3:299     Document Type: Review

References (188)

1. Sadovnick, D. and Lovestone, S. (2001) Genetic counselling, in Clinical Diagnosis and Management of Alzheimer's Disease? (Gauthier, S., ed.) Martin Dunitz, London, pp. 355-365.
2. Terry, R. D., Masliah, E., and Hansen, L. A. (1999) The neuropathology of Alzheimer's disease and the structural basis of its cognitive alterations, in Alzheimer's Disease (Terry, R. D., Katzman, R., and Bick, K. L., eds.) Raven Press, New York, pp. 187-206.
3. Goedert, M. (1998) Neurofibrillary pathology of Alzheimer's disease and other tauopathies Prog. Brain Res. 117, 287-306.
4. Avila, J., Lim, E, Moreno, E, Belmonte, C., and Cuello, A. C. (2002) Tau function and dysfunction in neurons: Its role in neurodegenerative disorders. Mol. Neurobiol. (In press.)
5. Haass, C., Schlossmacher, M. G., Hung, A. Y., et al. (1992) Amyloid b-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325.
6. Shoji, M., Golde, T. E., Ghiso, J., et al. (1992) Production of the Alzheimer amyloid b protein by normal proteolytic processing. Science 258, 126-129.
7. Walter, J., Kaether, C., Steiner, H., and Haass, C. (2001) The cell biology of Alzheimer's disease: Uncovering the secrets of secretases. Curr. Opin. Neurobiol. 11, 585-590.
8. Vassar, R. and Citron, M. (2000) Abeta-generating enzymes: Recent advances in beta- and gamma-secretase research. Neuron 27, 419-422.
9. Tamaoka, A., Sawamura, N., Odaka, A., Suzuki, N., Mizusawa, H., Shoji, S., and Mori, H. (1995) Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: Enzymelinked immunosorbent assay and immunocytochemical study. Brain Res. 679, 151-156.
10. Citron, M., Oltersdorf, T., Haass, C., et al. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360, 672-674.
11. Hardy, J. (1999) The shorter amyloid cascade hypothesis. Neurobiol. Aging 20, p. 85.
12. Selkoe, D. J. (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
13. Goate, A., Chartier-Harlin, M. C., Mullan, M., et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
14. Sherrington, R., Rogaev, E. I., Liang, Y., et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
15. Rogaev, E. I., Sherrington, R., Rogaeva, E. A., et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778.
16. Levy-Lahad, E., Wasco, W., Poorkaj, P., et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977.
17. Corder, E. H., Saunders, A. M., Strittmatter, W. J., et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
18. Strittmatter, W. J. (2000) Apolipoprotein E and Alzheimer's disease. Ann. NY Acad. Sci. 924, 91-92.
19. Poirier, J. (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17, 525-530.
20. Bales, K. R., Verina, T., Dodel, R. C., et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17, 263-264.
21. Poirier. J. (2000) Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. NY Acad. Sci. 924, 81-90.
22. Blacker, D. and Tanzi, R. E. (1998) The genetics of Alzheimer disease: Current status and future prospects. Arch. Neurol. 55, 294-296.
23. Nicoll, J. A., Mrak, R. E., Graham, D. I., et al. (2000) Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol. 47, 365-368.
24. Papassotiropoulos, A., Bagli, M., Feder, O., et al. (1999) Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease. Neurosci. Lett. 262, 171-174.
25. Kamboh, M. I., Ferrell, R. E., and DeKosky, S. T. (1998) Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene. Neurosci. Lett. 244, 65-68.
26. Yamanaka, H., Kamimura, K., Tanahashi, H., Takahashi, K., Asada, T., and Tabira, T. (1998) Genetic risk factors in Japanese Alzheimer's disease patients: Alphal-ACT, VLDLR, and ApoE Neurobiol. Aging 19, S43-S46.
27. Hu, Q., Kukull, W. A., Bressler, S. L., Gray, M. D., Cam, J. A., Larson, E. B., Martin, G. M., and Deeb, S. S. (1998) The human FE65 gene: Genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type. Hum. Genet. 103, 295-303.
28. Montoya, S. E., Aston, C. E., DeKosky, S. T., Kamboh, M. I., Lazo, J. S., and Ferrell, R. E. (1998) Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat. Genet. 18, 211-212.
29. Finckh, U., von der, K. H., Velden, J., et al. (2000) Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch. Neurol. 57, 1579-1583.
30. Jaffe, A. B., Toran-Allerand, C. D., Greengard, P., and Gandy, S. E. (1994) Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J. Biol. Chem. 269, 13,065-13,068.
31. Tang, M. X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., Andrews, H., and Mayeux, R. (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348, 429-432.
32. Xu, H., Sweeney, D., Wang, R., Thinakaran, G., Lo, A. C., Sisodia, S. S., Greengard, P., and Gandy, S. (1997) Generation of Alzheimer b-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc. Natl. Acad. Sci. USA 94, 3748-3752.
33. Zheng, H., Xu, H., Uljon, S. N., et al. (2002) Modulation of A(beta) peptides by estrogen in mouse models. J. Neurochem. 80, 191-196.
34. Chang, D., Kwan, J. and Timiras, P. S. (1997) Estrogens influence growth, maturation, and amyloid beta-peptide production in neuroblastoma cells and in a beta-APP transfected kidney 293 cell line. Adv. Exp. Med. Biol. 429, 261-271.
35. Mattson, M. P. and Chan, S. L. (2001) Dysregulation of cellular calcium homeostasis in Alzheimer's disease: Bad genes and bad habits. J. Mol. Neurosci. 17, 205-224.
36. Mattson, M. P. (2000) Neuroprotective signaling and the aging brain: Take away my food and let me run. Brain Res. 886, 47-53.
37. Borchelt, D. R., Thinakaran, G., Eckman, C. B., et al. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
38. Fraser, P. E., Yang, D. S., Yu, G., et al. (2000) Presenilin structure, function and role in Alzheimer disease. Biochim. Biophys. Acta. 1502, 1-15.
39. Chartier-Harlin, M. C., Crawford, F., Houlden, H., et al. (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844-846.
40. Haass, C., Lemere, C. A., Capell, A., et al. (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat. Med. 1, 1291-1296.
41. Citron, M., Westaway, D., Xia, W., et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Med. 3, 67-72.
42. Glabe, C. (2001) Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J. Mol. Neurosci. 17, 137-145.
43. Burger, P. C. and Vogel, F. S. (1973) The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am. J. Pathol. 73, 457-476.
44. Whalley, L. J. (1982) The dementia of Down's syndrome and its relevance to aetiological studies of Alzheimer's disease. Ann. NY Acad. Sci. 396, 39-53.
45. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82, 4245-4249.
46. Wisniewski, K. E., Wisniewski, H. M., and Wen, G. Y. (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17, 278-282.
47. Mann, D. M., Yates, P. O., Marcyniuk, B., and Ravindra, C. R. (1986) The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol. Appl. Neurobiol. 12, 447-457.
48. Cork, L. C. (1990) Neuropathology of Down syndrome and Alzheimer disease. Am. J. Med. Genet. Suppl 7, 282-286.
49. Fukuoka, Y., Fujita, T., and Ito, H. (1990) Histopathological studies on senile plaques in brains of patients with Down's syndrome Kobe. J. Med. Sci. 36, 153-171.
50. Hof, P. R., Bouras, C., Perl, D. P., Sparks, D. L., Mehta, N., and Morrison, J. H. (1995) Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch. Neurol. 52, 379-391.
51. Hyman, B. T., West, H. L., Rebeck, G. W., Lai, F., and Mann, D. M. (1995) Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch. Neurol. 52, 373-378.
52. Mann, D. M., Prinja, D., Davies, C. A., et al. (1989) Immunocytochemical profile of neurofibrillary tangles in Down's syndrome patients of different ages. J. Neurol. Sci. 92, 247-260.
53. Alvarez, A., Toro, R., Caceres, A., and Maccioni, R. B. (1999) Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 459, 421-426.
54. Morishima, Y., Gotoh, Y., Zieg, J., et al. (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 7551-7560.
55. Sheng, J. G., Jones, R. A., Zhou, X. Q., McGinness, J. M., Van Eldik, L. J., Mrak, R. E., and Griffin, W. S. (2001) Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: Potential significance for tau protein phosphorylation. Neurochem. Int. 39, 341-348.
56. Zhu, X., Castellani, R. J., Takeda, A., Nunomura, A., Atwood, C. S., Perry, G., and Smith, M. A. (2001) Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: The 'two hit' hypothesis. Mech. Ageing Dev. 123, 39-46.
57. Zhu, X., Rottkamp, C. A., Hartzler, A., et al. (2001) Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J. Neurochem. 79, 311-318.
58. Checler, F., da Costa, C. A., Ancolio, K., Chevallier, N., Lopez-Perez, E., and Marambaud, P. (2000) Role of the proteasome in Alzheimer's disease. Biochim. Biophys. Acta. 1502, 133-138.
59. McGeer, P. L. and McGeer, E. G. (1992) Complement proteins and complement inhibitors in Alzheimer's disease. Res. Immunol. 143, 621-624.
60. Emmerling, M. R., Watson, M. D., Raby, C. A., and Spiegel, K. (2000) The role of complement in Alzheimer's disease pathology. Biochim. Bio-phys. Acta. 1502, 158-171.
61. Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., and Perry, G. (2000) Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta. 1502, 139-144.
62. Varadarajan, S., Yatin, S., Aksenova, M., and Butterfield, D. A. (2000) Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184-208.
63. Nunomura, A., Perry, G., Aliev, G., et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767.
64. Nixon, R. A., Mathews, P. M. and Ctaldo, A. M. (2001) The neuronal endosomal-lysosomal system in Alzheimer's disease. J. Alz. Dis. 3, 97-107.
65. Casley, C. S., Canevari, L., Land, J. M., Clark, J. B., and Sharpe, M. A. (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80, 91-100.
66. Grant, S. M., Morinville, A., Maysinger, D., Szyf, M., and Cuello, A. C. (1999) Phosphorylation of mitogen-activated protein kinase is altered in neuroectodermal cells overexpressing the human amyloid precursor protein 751 isoform. Mol. Brain Res. 72, 115-120.
67. Canevari, L., Clark, J. B., and Bates, T. E. (1999) Beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett. 457, 131-134.
68. Parks, J. K., Smith, T. S., Trimmer, P. A., Bennett, J. P., Jr., and Parker, W. D., Jr. (2001) Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J. Neurochem. 76, 1050-1056.
69. Harkany, T., Hortobagyi, T., Sasvari, M., Konya, C., Penke, B., Luiten, P. G., and Nyakas, C. (1999) Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: Relevance to Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 963-1008.
70. Auld, D. S., Kar, S., and Quirion, R. (1998) Beta-amyloid peptides as direct cholinergic neuromodulators: A missing link? Trends Neurosci. 21, 43-49.
71. Kar, S., Seto, D., Gaudreau, P., and Quirion, R. (1996) Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J. Neurosci. 16, 1034-1040.
72. +]i in rat astrocytes. Biochem. Biophys. Res. Commun. 235, 479-481.
73. Lin, H., Bhatia, R., and Lal, R. (2001) Amyloid beta protein forms ion channels: Implications for Alzheimer's disease pathophysiology. FASEB J. 15, 2433-2444.
74. + homeostasis in Alzheimer's disease. Trends Neurosci. 16, 409-414.
75. Mattson, M. P. and Pedersen, W. A. (1998) Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int. J. Dev. Neurosci. 16, 737-753.
76. Tong, L., Thornton, P. L., Balazs, R., and Cotman, C. W. (2001) Beta-amyloid (1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J. Biol. Chem. 276, 17,301-17,306.
77. Ferrer, I., Blanco, R., Carmona, M., Puig, B., Dominguez, I., and Vinals, F. (2002) Active, phosphorylation-dependent MAP kinases, MAPK/ERK, SAPK/JNK and p38, and specific transcription factor substrates are differentially expressed following systemic administration of kainic acid to the adult rat. Acta. Neuropathol. (Berl.) 103, 391-407.
78. Cummings, B. J., Pike, C. J., Shankle, R., and Cotman, C. W. (1996) Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging 17, 921-933.
79. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
80. Naslund, J., Haroutunian, V., Mohs, R., Davis, K. L., Davies, P., Greengard, P., and Buxbaum, J. D. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
81. Chen, G., Chen, K. S., Knox, J., et al. (2000) A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408, 975-979.
82. Gordon, M. N., King, D. L., Diamond, D. M., et al. (2001) Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiol. Aging 22, 377-385.
83. Frautschy, S. A., Baird, A., and Cole, G. M. (1991) Effects of injected Alzheimer b-amyloid cores in rat brain. Proc. Natl. Acad. Sci. USA 88, 8362-8366.
84. Winkler, J., Connor, D. J., Frautschy, S. A., Behl, C., Waite, J. J., Cole, G. M., and Thal, L. J. (1994) Lack of long-term effects after beta-amyloid protein injections in rat brain. Neurobiol. Aging 15, 601-607.
85. Giovannelli, L., Casamenti, F., Scali, C., Bartolini, L., and Pepeu, G. (1995) Differential effects of amyloid peptides beta-(1-40) and beta-(25-35) injections into the rat nucleus basalis. Neuroscience 66, 781-792.
86. Giovannelli, L., Scali, C., Faussone-Pellegrini, M. S., Pepeu, G., and Casamenti, F. (1998) Long-term changes in the aggregation state and toxic effects of beta-amyloid injected into the rat brain. Neuroscience 87, 349-357.
87. Rush, D. K., Aschmies, S., and Merriman, M. C. (1992) Intracerebral beta-amyloid (25-35) produces tissue damage: Is it neurotoxic? Neurobiol. Aging 13, 591-594.
88. Koistinaho, M., Ort, M., Cimadevilla, J. M., Vondrous, R., Cordell, B., Koistinaho, J., Bures, J., and Higgins, L. S. (2001) Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. USA 98, 14,675-14,680.
89. Parvathy, S., Davies, P., Haroutunian, V., et al. (2001) Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch. Neurol. 58, 2025-2032.
90. Stephan, A., Laroche, S., and Davis, S. (2001) Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci. 21, 5703-5714.
91. Janus, C., Chishti, M. A., and Westaway, D. (2000) Transgenic mouse models of Alzheimer's disease. Biochim. Biophys. Acta. 1502, 63-75.
92. Morgan, D., Diamond, D. M., Gottschall, P. E., et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
93. Mobley, W. C., Neve, R. L., Prusiner, S. B., and McKinley, M. P. (1988) Nerve growth factor increases mRNA levels for the prion protein and the beta-amyloid protein precursor in developing hamster brain. Proc. Natl. Acad. Sci. USA 85, 9811-9815.
94. Rossner, S., Ueberham, U., Schliebs, R., Perez-Polo, J. R., and Bigl, V. (1998) The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56, 541-569.
95. Quon, D., Catalano, R., and Cordell, B. (1990) Fibroblast growth factor induces beta-amyloid precursor mRNA in ghal but not neuronal cultured cells. Biochem. Biophys. Res. Commun. 167, 96-102.
96. Caporaso, G. L., Gandy, S. E., Buxbaum, J. D., Ramabhadran, T. V., and Greengard, P. (1992) Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein. Proc. Natl. Acad. Sci. USA 89, 3055-3059.
97. Hung, A. Y., Haass, C., Nitsch, R. M., Qiu, W. Q., Citron, M., Wurtman, R. J., Growdon, J. H., and Selkoe, D. J. (1993) Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J. Biol. Chem. 268, 22,959-22,962.
98. Savage, M. J., Trusko, S. P., Howland, D. S., et al. (1998) Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci. 18, 1743-1752.
99. Haring, R., Fisher, A., Marciano, D., Pittel, Z., Kloog, Y., Zuckerman, A., Eshhar, N., and Heldman, E. (1998) Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the ml muscarinic receptor to beta-amyloid precursor protein secretion. J. Neurochem. 71, 2094-2103.
100. Johnson-Wood, K., Lee, M., Motter, R., et al. (1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 94, 1550-1555.
101. Koo, E. H. and Squazzo, S. L. (1994) Evidence that production and release of amyloid b-protein involves the endocytic pathway. J. Biol. Chem. 269, 17,386-17,389.
102. Perez, R. G., Squazzo, S. L., and Koo, E. H. (1996) Enhanced release of amyloid beta-protein from codon 670/671 "Swedish" mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways. J. Biol. Chem. 271, 9100-9107.
103. Cataldo, A. M., Barnett, J. L., Pieroni, C., and Nixon, R. A. (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17, 6142-6151.
104. Nixon, R. A., Cataldo, A. M., Paskevich, P. A., Hamilton, D. J., Wheelock, T. R., and Kanaley-Andrews, L. (1992) The lysosomal system in neurons. Involvement at multiple stages of Alzheimer's disease pathogenesis. Ann. NY Acad. Sci. 674, 65-88.
105. Gouras, G. K., Tsai, J., Naslund, J., et al. (2000) Intraneuronal Ab42 accumulation in human brain. Am. J. Pathol. 156, 15-20.
106. D'Andrea, M. R., Nagele, R. G., Wang, H. Y., Peterson, P. A., and Lee, D. H. (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38, 120-134.
107. Soriano, S., Chyung, A. S., Chen, X., Stokin, G. B., Lee, V. M., and Koo, E. H. (1999) Expression of beta-amyloid precursor protein-CD3gamma chimeras to demonstrate the selective generation of amyloid beta(1-40) and amyloid beta(1-42) peptides within secretory and endocytic compartments. J. Biol. Chem. 274, 32,295-32,300.
108. Grant, S. M., Ducatenzeiler, A., Szyf, M., and Cuello, A. C. (2000) Aβ immunoreactive material is present in several intracellular compartments in transfected, neuronally differentiated, P19 cells expressing the human amyloid β-protein precursor. J. Alz. Dis. 2, 207-222.
109. Hartmann, T. (1999) Intracellular biology of Alzheimer's disease amyloid beta peptide. Eur. Arch. Psychiatry Clin. Neurosci. 249, 291-298.
110. Cook, D. G., Forman, M. S., Sung, J. C., et al. (1997) Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nature Med. 3, 1021-1023.
111. Greenfield, J. P., Tsai, J., Gouras, G. K., et al. (1999) Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc. Natl. Acad. Sci. USA 96, 742-747.
112. Hartmann, T., Bieger, S. C., Bruhl, B., et al. (1997) Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nature Med. 3, 1016-1020.
113. Petanceska, S. S., Seeger, M., Checler, F., and Gandy, S. (2000) Mutant presenilin 1 increases the levels of Alzheimer amyloid beta-peptide Abeta42 in late compartments of the constitutive secretory pathway. J. Neurochem. 74, 1878-1884.
114. Martin, B. L., Schrader-Fischer, G., Busciglio, J., Duke, M., Paganetti, P., and Yankner, B. A. (1995) Intracellular accumulation of beta-amyloid in cells expressing the Swedish mutant amyloid precursor protein. J. Biol. Chem. 270, 26,727-26,730.
115. Higaki, J., Quon, D., Zhong, Z., and Cordell, B. (1995) Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14, 651-659.
116. Yamazaki, T., Selkoe, D. J., and Koo, E. H. (1995) Trafficking of cell surface beta-amyloid precursor protein: Retrograde and transcytotic transport in cultured neurons. J. Cell Biol. 129, 431-442.
117. Tienari, P. J., Ida, N., Ikonen, E., et al. (1997) Intracellular and secreted Alzheimer b-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 94, 4125-4130.
118. Haass, C., Hung, A. Y., Schlossmacher, M. G., et al. (1993) Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann. NY Acad. Sci. 695, 109-116.
119. Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13, 1676-1687.
120. Lorenzo, A. and Yankner, B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 91, 12,243-12,247.
121. Roher, A. E., Baudry, J., Chaney, M. O., Kuo, Y. M., Stine, W. B., and Emmerling, M. R. (2000) Oligomerizaiton and fibril assembly of the mayloid-beta protein. Biochim. Biophys. Acta. 1502, 31-43.
122. Skovronsky, D. M., Doms, R. W., and Lee, V. M. (1998) Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J. Cell Biol. 141, 1031-1039.
123. Lee, S. J., Liyanage, U., Bickel, P. E., Xia, W., Lansbury, P. T., Jr., and Kosik, K. S. (1998) A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 4, 730-734.
124. Mochizuki, A., Tamaoka, A., Shimohata, A., Komatsuzaki, Y., and Shoji, S. (2000) Abeta42 positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet 355, 42-43.
125. Walsh, D. M., Klyubin, I., Fadeeva, J. V., et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
126. Yankner, B. A., Dawes, L. R., Fisher, S., Villa-Komaroff, L., Oster-Granite, M. L., and Neve, R. L. (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417-420.
127. Yankner, B. A., Caceres, A., and Duffy, L. K. (1990) Nerve growth factor potentiates the neurotoxicity of beta amyloid. Proc. Natl. Acad. Sci. USA 87, 9020-9023.
128. Neve, R. L. and Robakis, N. K. (1998) Alzheimer's disease: A re-examination of the amyloid hypothesis. Trends Neurosci. 21, 15-19.
129. Kowall, N. W., Beal, M. F., Busciglio, J., Duffy, L. K., and Yankner, B. A. (1991) An in vivo model for the neurodegenerative effects of b amyloid and protection by substance P. Proc. Natl. Acad. Sci. USA 88, 7247-7251.
130. Harkany, T., O'Mahony, S., Kelly, J. P., et al. (1998) Beta-amyloid(Phe(SO3H)24)25-35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. Behav. Brain Res. 90, 133-145.
131. Geula, C., Wu, C. K., Saroff, D., Lorenzo, A., Yuan, M., and Yankner, B. A. (1998) Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4, 827-831.
132. Knauer, M. F., Soreghan, B., Burdick, D., Kosmoski, J., and Glabe, C. G. (1992) Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc. Natl. Acad. Sci. USA 89, 7437-7441.
133. Xia, W., Zhang, J., Ostaszewski, B. L., et al. (1998) Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry 37, 16,465-16,471.
134. Chui, D. H., Tanahashi, H., Ozawa, K., et al. (1999) Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. 5, 560-564.
135. Wirths, O., Multhaup, G., Czech, C., Blanchard, V., et al. (2001) Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 306, 116-120.
136. Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., and Troncoso, J. C. (2001) Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 125, 489-492.
137. Yang, A. J., Knauer, M., Burdick, D. A., and Glabe, C. (1995) Intracellular A beta 1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J. Biol. Chem. 270, 14,786-14,792.
138. Burdick, D., Kosmoski, J., Knauer, M. F., and Glabe, C. G. (1997) Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, A beta 1-42, in differentiated PC12 cells. Brain Res. 746, 275-284.
139. Smith, M. A. and Perry, G. (1995) Free radical damage, iron, and Alzheimer's disease. J. Neurol. Sci. 134 Suppl, 92-94.
140. Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., and Ball, M. J. (1993) Beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 10,836-10,840.
141. Bahr, B. A., Hoffman, K. B., Yang, A. J., Hess, U. S., Glabe, C. G., and lynch, G. (1998) Amyloid beta protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J. Comp Neurol. 397, 139-147.
142. Burdick, D., Soreghan, B., Kwon, M., et al. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. 267, 546-554.
143. Yang, A. J., Chandswangbhuvana, D., Shu, T., Henschen, A., and Glabe, C. G. (1999) Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J. Biol. Chem. 274, 20,650-20,656.
144. Cataldo, A. M., Thayer, C. Y., Bird, E. D., Wheelock, T. R., and Nixon, R. A. (1990) Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: Evidence for a neuronal origin. Brain Res. 513, 181-192.
145. Omar, R., Pappolla, M., Argani, I., and Davis, K. (1993) Acid phosphatase activity in senile plaques and cerebrospinal fluid of patients with Alzheimer's disease. Arch. Pathol. Lab. Med. 117, 166-169.
146. Sze, C. I., Troncoso, J. C., Kawas, C., Mouton, P., Price, D. L., and Martin, L. J. (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 933-944.
147. Masliah, E., Mallory, M., Hansen, L., DeTeresa, R., Alford, M., and Terry, R. (1994) Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 174, 67-72.
148. Koistinaho, M., Kettunen, M. I., Goldsteins, G., et al. (2002) Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation. Proc. Natl. Acad. Sci. USA 99, 1610-1615.
149. Tabira, T., Chui, D. H., and Kuroda, S. (2002) Significance of intracellular Abeta42 accumulation in Alzheimer's disease. Front Biosci. 7, a44-a49.
150. LaFerla, F. M., Troncoso, J. C., Strickland, D. K., Kawas, C. H., and Jay, G. (1997) Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J. Clin. Invest 100, 310-320.
151. Hsia, A. Y., Masliah, E., McConlogue, L., et al. (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96, 3228-3233.
152. Himmler, A., Drechsel, D., Kirschner, M. W., and Martin, D. W., Jr. (1989) Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol. Cell Biol. 9, 1381-1388.
153. Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., and Crowther, R. A. (1989) Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526.
154. Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., and Klug, A. (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA 85, 4051-4055.
155. Otvos, L., Jr., Feiner, L., Lang, E., Szendrei, G. I., Goedert, M., and Lee, V. M. (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39, 669-673.
156. Crowther, T., Goedert, M., and Wischik, C. M. (1989) The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease. Ann. Med. 21, 127-132.
157. Crowther, R. A., Olesen, O. F., Jakes, R., and Goedert, M. (1992) The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer's disease. FEBS Lett. 309, 199-202.
158. Crowther, R. A., Olesen, O. F., Smith, M. J., Jakes, R., and Goedert, M. (1994) Assembly of Alzheimer-like filaments from full-length tau protein. FEBS Lett. 337, 135-138.
159. Mandelkow, E. M. and Mandelkow, E. (1998) Tau in Alzheimer's disease. Trends Cell Biol. 8, 425-427.
160. Iqbal, K., Alonso, A. D., Gondal, J. A., et al. (2000) Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J. Neural Transm. 59 Suppl, 213-222.
161. Dustin, P. and Flament-Durand, J. (1982) Disturbances of axoplasmic transport in Alzheimer's disease, in Axoplasmic Transport and Pathology. (Weiss, D. G. and Gorio, A., eds.) Springer-Verlag, Berlin, pp. 131-136.
162. Grundke-Iqbal, I. and Iqbal, K. (1999) Tau pathology generated by overexpression of tau. Am. J. Pathol. 155, 1781-1785.
163. Mena, R., Wischik, C. M., Novak, M., Milstein, C., and Cuello, A. C. (1991) A progressive deposition of paired helical filaments (PHF) in the brain characterizes the evolution of dementia in Alzheimer's disease. An immunocytochemical study with a monoclonal antibody against the PHF core. J. Neuropathol. Exp. Neurol. 50, 474-490.
164. Wischik, C. M., Harrington, C. R., Mukaetova-Ladinska, E. B., Novak, M., Edwards, P. C., and McArthur, F. K. (1992) Molecular characterization and measurement of Alzheimer's disease pathology: Implications for genetic and environmental aetiology. Ciba Found. Symp. 169, 268-293.
165. Holzer, M., Holzapfel, H.-P., Zedlick, D., Brückner, M. K., and Arendt, T. (1994) Abnormally phosphorylated tau protein in Alzheimer's disease: Heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience 63, 499-516.
166. Trojanowski, J. Q. and Lee, V. M. (1994) Paired helical filament tau in Alzheimer's disease. The kinase connection. Am. J. Pathol. 144, 449-453.
167. Jellinger, K. A. and Bancher, C. (1998) Senile dementia with tangles (tangle predominant form of senile dementia). Brain Pathol. 8, 367-376.
168. Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R. M. (2001) Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495.
169. Lewis, J., Dickson, D. W., Lin, W. L., et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
170. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., and Hof, P. R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130.
171. Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P., and Anderton, B. H. (1992) Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147, 58-62.
172. Tomidokoro, Y., Harigaya, Y., Matsubara, E., et al. (2001) Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J. Pathol. 194, 500-506.
173. Takahashi, M., Tomizawa, K., Sato, K., Ohtake, A., and Omori, A. (1995) A novel tau-tubulin kinase from bovine brain. FEBS Lett. 372, 59-64.
174. Drewes, G., Lichtenberg-Kraag, B., Doring, F., et al. (1992) Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 11, 2131-2138.
175. Liu, W. K., Williams, R. T., Hall, F. L., Dickson, D. W., and Yen, S. H. (1995) Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments. Am. J. Pathol. 146, 228-238.
176. Drewes, G., Ebneth, A., Preuss, U., et al. (1997) A novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89, 297-308.
177. 2+/calmodulin-dependent protein kinase II: Metabolic and functional consequences. J. Neurochem. 59, 2056-2062.
178. Litersky, J. M. & Johnson, G. V. (1992) Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain. J. Biol. Chem. 267, 1563-1568.
179. Greenwood, J. A., Scott, C. W., Spreen, R. C., Caputo, C. B., and Johnson, G. V. (1994) Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert. Identification of threonine 39 as the primary phosphate acceptor. J. Biol. Chem. 269, 4373-4380.
180. Goedert, M., Cuenda, A., Craxton, M., Jakes, R., and Cohen, P. (1997) Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J. 16, 3563-3571.
181. Reynolds, C. H., Utton, M. A., Gibb, G. M., Yates, A., and Anderton, B. H. (1997) Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein J. Neurochem. 68, 1736-1744.
182. Imahori, K., Hoshi, M., Ishiguro, K., et al. (1998) Possible role of tau protein kinases in pathogenesis of Alzheimer's disease. Neurobiol. Aging 19, S93-S98.
183. Augustinack, J. C., Schneider, A., Mandelkow, E. M., and Hyman, B. T. (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta. Neuropathol. (Berl.) 103, 26-35.
184. Perry, G., Roder, H., Nunomura, A., et al. (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. NeuroReport 10, 2411-2415.
185. Knowles, R. B., Chin, J., Ruff, C. T., and Hyman, B. T. (1999) Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: Implications for MAP kinase activation in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58, 1090-1098.
186. Ferrer, I., Blanco, R., Carmona, M., and Puig, B. (2001) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural Transm. 108, 1397-1415.
187. Greenberg, S. M., Koo, E. H., Selkoe, D. J., Qiu, W. Q., and Kosik, K. S. (1994) Secreted β-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc. Natl. Acad. Sci. USA 91, 7104-7108.
188. 751). NeuroReport 10, 41-46.